Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
Age-related NAD+ decline
Its considered an investigational compound in many places and is not universally approved for medical use, but it remains under research for weight-management applications
Future studies are expected to elucidate the safety and efficacy of 5-amino-1MQ, identifying specific populations that may benefit or experience adverse effects
2001, AOD-9604 lost most of this fat-metabolism effect in mice that were genetically missing the beta-3 adrenergic receptor, suggesting that pathway carries part of the signal
As of June 2026, the FDA's December 2024 Pharmacy Compounding Advisory Committee evaluation concluded that the criteria weighed against placing AOD-9604 (free base) or AOD-9604 acetate on the 503A Bulks List, and AOD-9604 is currently listed as Nominated but Withdrawn from FDA Category 2
US$ 23.57
US$ 22.82
US$ 26.14
US$ 28.76
US$ 23.52
US$ 28.90
US$ 22.50